Concetta Elisa Onesti
Concetta Elisa Onesti
Unknown affiliation
Verified email at uniroma1.it
Title
Cited by
Cited by
Year
A microRNA signature defines chemoresistance in ovarian cancer through modulation of angiogenesis
A Vecchione, B Belletti, F Lovat, S Volinia, G Chiappetta, S Giglio, ...
Proceedings of the National Academy of Sciences 110 (24), 9845-9850, 2013
1832013
The use of bevacizumab in non-small cell lung cancer: an update
S Lauro, CE Onesti, R Righini, P Marchetti
Anticancer research 34 (4), 1537-1545, 2014
842014
The sexist behaviour of immune checkpoint inhibitors in cancer therapy?
A Botticelli, CE Onesti, I Zizzari, B Cerbelli, P Sciattella, M Occhipinti, ...
Oncotarget 8 (59), 99336, 2017
402017
High-doses of proton pump inhibitors in refractory gastro-intestinal cancer: A case series and the state of art
R Falcone, M Roberto, C D’Antonio, A Romiti, A Milano, CE Onesti, ...
Digestive and Liver Disease 48 (12), 1503-1505, 2016
272016
Lean body mass wasting and toxicity in early breast cancer patients receiving anthracyclines
F Mazzuca, CE Onesti, M Roberto, M Di Girolamo, A Botticelli, P Begini, ...
Oncotarget 9 (39), 25714, 2018
252018
Continuous, low-dose capecitabine for patients with recurrent colorectal cancer
A Romiti, CE Onesti, M Roberto, V Barucca, S Tomao, C D’Antonio, ...
Medical Oncology 32 (3), 54, 2015
252015
Pharmacogenomics in lung cancer chemotherapy: a review of what the oncologist should know
C D'ANTONIO, A Milano, R Righini, CE Onesti, M Bassanelli, R Falcone, ...
Anticancer research 34 (10), 5241-5250, 2014
222014
Prognosis of elderly gastric cancer patients after surgery: a nomogram to predict survival
M Roberto, A Botticelli, L Strigari, M Ghidini, CE Onesti, M Ratti, I Benzoni, ...
Medical oncology 35 (7), 1-9, 2018
172018
Precision medicine for metastatic breast cancer.
AF Deluche E, Onesti E
Am Soc Clin Oncol Educ Book 35, e2-e7, 2015
172015
Molecular detection of EMT markers in circulating tumor cells from metastatic non-small cell lung cancer patients: potential role in clinical practice
A Milano, F Mazzetta, S Valente, D Ranieri, L Leone, A Botticelli, ...
Analytical Cellular Pathology 2018, 2018
162018
Recent advances for the treatment of pancreatic and biliary tract cancer after first-line treatment failure
CE Onesti, A Romiti, M Roberto, R Falcone, P Marchetti
Expert review of anticancer therapy 15 (10), 1183-1198, 2015
142015
Atypical patterns of response to immune checkpoint inhibitors: interpreting pseudoprogression and hyperprogression in decision making for patients’ treatment
CE Onesti, P Frères, G Jerusalem
Journal of thoracic disease 11 (1), 35, 2019
132019
A metronomic schedule as salvage chemotherapy for upper gastrointestinal tract cancer
M Roberto, A Romiti, CE Onesti, C D’Antonio, A Milano, R Falcone, ...
Anti-cancer drugs 27 (2), 106-111, 2016
132016
Hyperprogressive disease and early hypereosinophilia after anti-PD-1 treatment: a case report
M Occhipinti, R Falcone, CE Onesti, P Marchetti
Drug safety-case reports 5 (1), 1-4, 2018
102018
Evaluation of 5-fluorouracil degradation rate and Pharmacogenetic profiling to predict toxicity following adjuvant Capecitabine
M Roberto, A Romiti, A Botticelli, F Mazzuca, L Lionetto, G Gentile, I Paris, ...
European journal of clinical pharmacology 73 (2), 157-164, 2017
102017
Oncological care organisation during COVID-19 outbreak
CE Onesti, HS Rugo, D Generali, M Peeters, K Zaman, H Wildiers, ...
ESMO open 5 (4), e000853, 2020
92020
Changes of microbiome profile during nivolumab treatment in NSCLC patients.
A Botticelli, L Putignani, I Zizzari, F Del Chierico, S Reddel, F Di Pietro, ...
Journal of Clinical Oncology 36 (15_suppl), e15020-e15020, 2018
92018
5-Fluorouracil degradation rate could predict toxicity in stages II–III colorectal cancer patients undergoing adjuvant FOLFOX
CE Onesti, A Botticelli, M La Torre, M Borro, G Gentile, A Romiti, ...
Anti-cancer drugs 28 (3), 322-326, 2017
92017
Pre-treatment assay of 5-fluorouracil degradation rate (5-FUDR) to improve prediction of 5-fluorouracil toxicity in gastro-esophageal cancer
M Borro, A Botticelli, F Mazzuca, EC Onesti, G Gentile, A Romiti, ...
Oncotarget 8 (8), 14050, 2017
92017
The TYMS-TSER polymorphism is associated with toxicity of low-dose capecitabine in patients with advanced gastrointestinal cancer
A Romiti, M Roberto, C D’Antonio, CE Onesti, V Barucca, A Milano, ...
Anti-cancer drugs 27 (10), 1044-1049, 2016
92016
The system can't perform the operation now. Try again later.
Articles 1–20